Just Earth News | @justearthnews | 03 Dec 2020, 08:45 pm Print
Wikimedia Pfizer
Washington/Sputnik: US drug giant Pfizer expects to ship just about half of the COVID-19 vaccines it originally planned for this year because of supply-chain problems, although it still expects to roll out more than a billion doses in 2021, the Wall Street Journal reported.
Scaling up the raw material supply chain took longer than expected, a Pfizer spokesperson told the newspaper on Thursday. The outcome of the clinical trial, the spokesperson added, was somewhat later than the initial projection.
New York-headquartered Pfizer and Germany-based partner BioNTech SE had hoped to roll out 100 million vaccines world-wide by the end of this year, a plan that has now been reduced to 50 million, the report said.
The United Kingdom on Wednesday granted emergency-use authorization for the vaccine, becoming the first Western country to start administering doses.
The two-shot Pfizer vaccine is also being reviewed by the US Food and Drug Administration, where a similar authorization could come later this month and a rollout before the end of the year. The US regulator also is considering a vaccine developed by Cambridge, Mass.-based Moderna Inc. that could begin shipping before Christmas.
- Medical experts propose new definitions of obesity which is not only about BMI
- Avian flu risk still remains 'low' despite US registering first death due to H5N1 virus, says WHO
- New COVID-19-like viral outbreak hits China
- Avian flu reported in 108 countries, alerts UN health agency
- Birth registration increases, but 150 million children still ‘invisible’, shows new UNICEF report
